OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Published 2019 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume -, Issue -, Pages -

Publisher

Oxford University Press (OUP)

Online

2019-01-16

DOI

10.1093/annonc/mdz012

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Publish scientific posters with Peeref

Ask a Question. Answer a Question.